The anti-CD20 monoclonal antibody rituximab is a highly effective treatment for PV, although less is known regarding its efficacy in the treatment of PF and the dynamics of anti-Dsg1 IgG subclasses post rituximab treatment. This evidence concerns the gene DSG1 and pemphigus foliaceus.